Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections

摘要

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality.nIsavuconazole (BAL4815) is a promising novel broad-spectrum triazole in latestagenclinical development that has proven to be active in vitro against Aspergillus,nCandida and Cryptococcus neoformans, the most common agents of IFIs.nFurthermore, isavuconazole has a pharmacokinetic profile that allows oral andnintravenous administration with no severe toxicity. In vivo data from animal modelsnare also encouraging. However, very little information on clinical efficacy isnavailable. Four clinical trials are currently in progress to demonstrate the safetynand efficacy of isavuconazole for the treatment and prevention of IFIs. In thenabsence of clinical and cost data, the real possibilities of this agent as a competitornfor the treatment and prevention of IFIs in the clinical setting are still unknown.